Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance
The Committee backed the combination based on results from the CAPItello-281 Phase III trial, marking a key milestone in the regulatory pathway for AstraZeneca’s targeted therapy strategy in prostate cancer
Lifts full-year outlook as obesity drug boom accelerates
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
Rahul Bhatnagar succeeds Aditya Narayan, who completed a decade-long distinguished tenure
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
The microbiology unit generated $645 million in revenue in 2025 and sits within Thermo Fisher’s Specialty Diagnostics segment
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
Subscribe To Our Newsletter & Stay Updated
